MarketFriction

Concord Biotech Ltd

NSE CONCORDBIO · BSE 543960 · Pharmaceuticals
₹1,374.10 +0.04%
NSE close2026-10-01
52 week range987.00 - 1,667.60
Market cap₹14,758 Cr.
P/E51.9
IPO 2023 · +85% since Nifty 500Smallcap 250 Price band 20% Delivery 47.7%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales262241319216310244430204247278326261
Expenses143135185135174146239143157176204173
Operating Profit1191061348113798190619110212287
OPM %45%44%42%38%44%40%44%30%37%37%38%33%
Other Income88111010159141371613
Interest100000000000
Depreciation131414131313151818191918
Profit before tax113100131781339918557869011882
Tax %25%26%26%25%26%25%23%26%26%25%24%26%
Net Profit8475975899741424363689061
EPS in Rs8.087.139.295.579.437.0813.574.076.016.488.605.85
Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2392763404365126177138531,0171,2001,0551,112
Expenses133145212256308289439509585693678709
Operating Profit105131127180205328274344432507377402
OPM %44%48%37%41%40%53%38%40%42%42%36%36%
Other Income11836173114233534444949
Interest101111653110
Depreciation101018192128505454547475
Profit before tax106129144178213313241320409496351376
Tax %34%33%30%33%21%25%26%26%26%25%25%
Net Profit7087100118169235179238305373263282
EPS in Rs76.3294.78105.66124.48177.65247.44187.7622.7629.1335.6525.1726.94
Dividend Payout %22%25%0%21%22%0%3%30%30%25%30%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth14%11%7%-6%
Compounded Profit Growth11%1%1%-20%
Stock Price CAGR%%9%-14%
Return on Equity%18%18%13%
Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital99101010101010101010
Reserves2683295856737619901,0981,2821,5151,8022,009
Borrowings3536229528962321031
Other Liabilities5574697111894144191164219216
Total Liabilities3674486857639411,1831,3131,5151,6992,0342,237
Fixed Assets104110189230240546573593575795786
CWIP197031914118741732115179
Investments424315122919914274138244335488
Other Assets202225343285361477592611668854883
Total Assets3674486857639411,1831,3131,5151,6992,0342,237
Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity79155167207246265245264
Cash from Investing Activity-42-114-195-112-158-155-160-142
Cash from Financing Activity-37-4331-100-85-99-99-115
Net Cash Flow0-13-4312-147
Free Cash Flow79-1-3752101180134169
CFO/OP101%100%74%98%92%85%70%96%
Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days165182236133131105119117125159159
Inventory Days276321381310312503434430331286483
Days Payable108129210112201152185190150135150
Cash Conversion Cycle334374407331242456368357306310492
Working Capital Days195209275177159177163153166193231
ROCE %37%25%25%32%21%26%28%28%17%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.08%
FIIs7.30%7.00%6.49%7.11%8.10%8.33%9.35%9.10%8.03%7.58%7.79%7.53%
DIIs8.12%8.40%8.41%10.35%9.89%9.65%9.16%8.85%9.55%9.58%9.22%9.37%
Public40.50%40.52%41.03%38.46%37.95%37.93%37.41%37.94%38.32%38.75%38.90%39.04%
No. of Shareholders1,00,92787,48683,29680,73784,29882,00481,21982,04582,65081,81582,24983,325

Fundamentals

Market Cap₹ 14,758 Cr.
Current Price₹ 1,411
Stock P/E51.9
Book Value₹ 193
ROCE17.4 %
ROE12.6 %
Dividend Yield0.54 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)-6%
Compounded Profit Growth (TTM)-20%
Standalone figures.
Valuation
Market capRs 14,375 Cr
Enterprise valueRs 14,367 Cr
P/E (TTM)51.00x
Price to book7.12x
Price to sales12.93x
EV / EBITDA31.84x
EV / EBIT38.15x
EV / sales12.92x
Price to cash flow54.50x
Earnings yield1.96%
Dividend yield0.55%
P/E, 3-year average46.61x
P/B, 3-year average8.47x
P/E, 5-year average46.61x
P/B, 5-year average8.47x
Profitability
Operating margin (excl. other income)35.74%
Operating margin (incl. other income)40.43%
EBITDA margin40.59%
Pre-tax margin33.86%
Net profit margin25.36%
Net margin, latest quarter23.49%
ROE13.74%
ROCE18.36%
ROA12.33%
ROE, 3-year average19.24%
ROCE, 3-year average25.63%
ROA, 3-year average17.09%
ROE, 5-year average18.90%
ROCE, 5-year average24.97%
ROA, 5-year average16.48%
ROIC (approx.)14.03%
Tax rate25.09%
Other income / net worth2.45%
Growth
Sales growth (latest year)-12.08%
Profit growth (latest year)-29.41%
Sales CAGR, 3 years7.34%
Sales CAGR, 5 years11.33%
Profit CAGR, 3 years3.40%
Profit CAGR, 5 years2.27%
Sales growth QoQ-20.06%
Profit growth QoQ-32.03%
Sales growth YoY (latest quarter)27.71%
Profit growth YoY (latest quarter)43.74%
Per share
EPS (TTM)Rs 26.95
EPS (latest year)Rs 25.17
EPS (latest quarter)Rs 5.85
EPS, 3-year averageRs 29.98
EPS, 5-year averageRs 60.09
Book value per shareRs 193.06
Sales per shareRs 106.26
Cash flow per shareRs 25.21
Free cash flow per shareRs 16.15
Dividend per share (latest year)Rs 7.55
Dividend per share, 3-year averageRs 8.35
Dividend per share, 5-year averageRs 7.40
Dividends
Dividend payout30.00%
Dividend payout, 3-year average28.19%
Dividend payout, 5-year average23.46%
Efficiency
Asset turnover0.47x
Fixed asset turnover1.34x
Inventory turnover1.21x
Inventory days303 days
Debtor days159 days
Debtors turnover2.29x
Creditor days150 days
Cash conversion cycle492 days
Working capital days231 days
Leverage
Total debtRs 1 Cr
Cash and bankRs 9 Cr
Net debtRs -9 Cr
Debt to equity0.00x
Net debt / EBITDA-0.02x
Interest coverage1883.00x
Current ratio (filing 2026-03-31)7.45x
Quick ratio (filing 2026-03-31)5.50x
Trade payables (filing 2026-03-31)Rs 101 Cr
Owners' fund to total sources90.31%
Debt to assets0.03%
Cash flow
Cash from Operating Activity (latest year)Rs 264 Cr
Cash from Investing Activity (latest year)Rs -142 Cr
Cash from Financing Activity (latest year)Rs -115 Cr
Net Cash Flow (latest year)Rs 7 Cr
Free cash flow (latest year)Rs 169 Cr
FCFE (approx.: FCF + change in debt)Rs 167 Cr
Cash from ops / profit, 5 years0.90x
Sales to cash flow4.00x
Statement figures
Net sales (TTM)Rs 1,112 Cr
Net sales (latest year)Rs 1,055 Cr
Sales (latest quarter)Rs 261 Cr
Operating profit excl. other income (latest year)Rs 377 Cr
Operating profit (latest quarter)Rs 87 Cr
Other income (TTM)Rs 49 Cr
EBITDA (TTM)Rs 451 Cr
PBDT (TTM)Rs 451 Cr
Profit before tax (TTM)Rs 376 Cr
Tax (latest year)Rs 88 Cr
Net profit (TTM)Rs 282 Cr
Net profit (latest year)Rs 263 Cr
Net profit (latest quarter)Rs 61 Cr
Depreciation (TTM)Rs 75 Cr
Depreciation (latest quarter)Rs 18 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 393 Cr
Total expenditure (latest year)Rs 678 Cr
Total income (latest year)Rs 1,105 Cr
Share capitalRs 10 Cr
ReservesRs 2,009 Cr
Shareholders' fundsRs 2,020 Cr
Total assetsRs 2,237 Cr
Net blockRs 786 Cr
Capital work in progressRs 79 Cr
InvestmentsRs 488 Cr
ReceivablesRs 461 Cr
InventoryRs 326 Cr
Other liabilitiesRs 216 Cr
Shares outstanding (crore)10.46
Ownership
Promoter holding44.08% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 51.0 is at the 49th percentile of its own 3.2-year range (median 51.0, low 33.8, high 75.9).
P/B 7.12 is at the 18th percentile (median 10.26).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodCONCORDBIONifty 50Difference
1 week-7.1%-2.8% -4.3 pts
1 month-7.4%-6.8% -0.6 pts
3 months+7.8%-7.6% +15.4 pts
6 months+34.9%+0.4% +34.5 pts
1 year-13.5%-9.9% -3.6 pts
2 years-42.3%-13.6% -28.8 pts
3 years+26.8%+14.2% +12.6 pts
52 mutual fund schemes hold about ₹919 Cr. Over three months 12 bought more and 9 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
DSP Small Cap Fund1.75%379 +87%
SBI Healthcare Opp Fund2.40%139 +21%
DSP Healthcare Fund2.77%106 +42%
Edelweiss Small Cap Fund1.13%82 -5%
Quant Healthcare Fund7.03%30 -26%
Invesco India Flexi Cap Fund0.45%26 -3%
Helios Mid Cap Fund0.88%20 +100%
Altiva Equity Ex-Top 100 Long-Short Fund1.91%18 -12%
ITI Flexi Cap Fund1.06%17 -10%
SBI Balanced Hybrid Fund0.92%17 +100%
Nippon India Pharma Fund0.17%16 -0%
Helios Small Cap Fund0.87%13 +100%
Baroda BNP Paribas Innovation Fund1.26%12 +1%
Canara Rob Manufacturing Fund0.65%11 +21%
Baroda BNP Paribas Health and Wellness Fund2.14%11 +14%
Nippon India Nifty Smallcap 250 Index Fund0.22%8 +1%
SBI Nifty Smallcap 250 Index Fund0.22%4 +1%
Motilal Oswal Nifty Smallcap 250 Index Fund0.22%3 +1%
ICICI Pru Nifty Smallcap 250 Index Fund0.22%2 +1%
HDFC NIFTY Smallcap 250 Index Fund0.22%2 +1%
Nippon India Nifty 500 Equal Weight Index Fund0.22%1 +1%
JioBlackRock Nifty Smallcap 250 Index Fund0.22%1 +1%
Motilal Oswal Nifty 500 Index Fund0.02%1 +1%
Edelweiss Nifty Smallcap 250 Index Fund0.22%1 +1%
Groww Nifty Smallcap 250 Index Fund0.22%0 +1%

Red flags

F-score 5 of 8
lookInventory outrunning sales Inventory grew 36% vs sales -12% in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹261 Cr +27.9% vs Jun 2025. Net profit ₹61 Cr +41.9%.
Against our estimate for Jun 2026: sales +34.9%, profit +26.2% in line. Our estimate for Sep 2026: sales Rs 252 Cr, profit Rs 63 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-07-24Dividend - Rs 7.55 Per Share
2025-09-03Dividend - Rs 10.70 Per Share
2024-06-21Dividend - Rs 8.75 Per Share
2024-06-21Annual General Meeting
DateTypeWhat it says
2026-09-24Shareholder meetingNotice of Postal Ballot
2026-09-23BonusThe Board of Directors at its meeting held on September 23, 2026, have considered and approved bonus at the ratio of 1 : 1, i.e 1 Equity Shares for ev...
2026-09-18General UpdatesIntimation of Outcome of U.S. Food and Drug Administration (USFDA) Inspection at Unit II Valthera Formulation Facility of the Company
2026-09-17Concall / analyst meetSchedule of meet
2026-08-21Concall / analyst meetSchedule of meet
2026-08-07Concall / analyst meetTranscript
2026-08-03Concall / analyst meetLink of Recording
2026-08-01Concall / analyst meetPresentation
2026-08-01Shareholder meetingVoting results.
2026-07-31Shareholder meetingProceedings of Annual General Meeting held on July 31, 2026
2026-07-31Board meeting outcomeConcord Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-28Concall / analyst meetSchedule of meet
2026-07-07Record DateRecord date for the purpose of Dividend & Meeting is 24-Jul-2026.
2026-07-07Shareholder meetingNotice of Annual General Meeting to be held on July 31, 2026
2026-06-25UpdatesCompletion of Inspection by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda at Unit-II formulation f...
2026-06-20AcquisitionAcquisition
2026-06-19Concall / analyst meetSchedule of meet
2026-06-13Concall / analyst meetSchedule of meet
2026-06-12UpdatesCompletion of ANVISA Inspection conducted by the Brazilian Health Regulatory Agency at the Limbasi API Manufacturing Facility.
2026-06-10General UpdatesConcord Biotech Secures Abbreviated New Drug Application (ANDA) Approval for Tofacitinib Tablets, 5 mg and 10 mg
2026-06-05Concall / analyst meetTranscript
2026-06-02UpdatesAbbreviated New Drug Application (ANDA) Approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
2026-06-01Concall / analyst meetLink of Recording
2026-05-30Investor PresentationInvestor Presentation
2026-05-30Board meeting outcomeConcord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)

Quick answers

What is the market cap of Concord Biotech Ltd?

Concord Biotech Ltd (CONCORDBIO) has a market capitalisation of Rs 14,758 Cr. at the 2026-10-01 close.

What is the P/E ratio of Concord Biotech Ltd?

Concord Biotech Ltd trades at a P/E of 51.9 on trailing twelve-month profit, at the 2026-10-01 close.

What were Concord Biotech Ltd's latest quarterly results?

In the Jun 2026 quarter, Concord Biotech Ltd sales was Rs 261 Cr (+27.9% vs Jun 2025) and net profit was Rs 61 Cr.

What is the 52-week high and low of Concord Biotech Ltd?

The 52-week high is Rs 1,667.60 and the 52-week low is Rs 987.00.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03